New atrial fibrillation drugs possess significant advantages over warfarin for reducing the risk of embolic events such as a stroke or peripheral embolism. Patients with AFib have an especially high risk of blood clots that can lead to stroke. Warfarin (Coumadin) has been the gold standard for stroke prevention in patients with AFib for the past 50 years. But to be effective, warfarin requires careful monitoring. Within the last several years, the FDA has approved several new anticoagulants as alternatives to warfarin: dabigatran (Pradaxa), a direct thrombin inhibitor; rivaroxaban (Xarelto), a factor Xa inhibitor; and apixaban (Eliquis), also a factor...